Yuwei Liu

This study suggested the possible application of FAPI radioligand therapy in FAP-expressing pancreatic cancer. Further evaluation is necessary to find the best radionuclide with shorter half-life, as well as the combination with therapies targeting tumour cells directly.

We recently reported the dose-dependent therapeutic effect of ²¹¹At-NaAt in differentiated thyroid cancer xenograft models. In the present study, we evaluated the radiation-induced toxicity of ²¹¹At-NaAt using detailed hematological, biochemical, and histological analyses. Biodistribution of ²¹¹At-NaAt was measured in normal ICR mice (n = 12), absorbed doses in the major organs were calculated. Groups of ICR mice (n = 60) were injected with 0.1 MBq or 1 MBq of <s

Abstract Purpose Fibroblast activation protein (FAP), which has high expression in cancer-associated fibroblasts of epithelial cancers, can be used as a theranostic target. Our previous study used 64 Cu and 225 Ac-labelled FAP inhibitors (FAPI-04) for a FAP-expressing pancreatic cancer xenograft imaging and therapy. However, the optimal therapeutic radionuclide for FAPI still needs to be further investigated. In this study, we evaluated the therapeutic effects of beta-emitter( 177 Lu)-labelled F

98 Purpose: Astatine(211At), an alpha-emitter with similar chemical properties to iodine, is expected to have a better therapeutic effect compared to 131I (beta-emitter). In the previous study, we revealed the dose-dependent therapeutic effect of 211At-NaAt solution by K1-NIS xenograft mice. In this study, we aimed to prove the better therapeutic effect of 211At-NaAt than 131I-NaI in differentiated thyroid cancer model. Methods: Colony assay and DNA double-strand break (DSB) assay were performe

1224 Purpose: We have recently reported the dose-dependent therapeutic effect of 211At-NaAt in differentiated thyroid cancer xenograft models. In this study, we evaluated the radiation-induced toxicity of 211At-NaAt using detailed hematological, biochemical, and histological analyses. Methods: Biodistribution of 211At-NaAt was measured in the normal ICR mice (n = 9, 38.2 ± 1.1 g), and the absorbed doses in the major organs were calculated. ICR mice groups (n = 60, 38.3 ± 1.9 g) were injected wi

1256 Purpose: An alpha-emitter, astatine(211At), can be used for the targeted alpha therapy of differentiated thyroid cancer. We have shown the dose-dependent treatment effect of 211At-NaAt solution using K1-NIS xenograft mice by single intravenous administration. In this study, we evaluated the therapeutic effect of repeated administration of 211At-NaAt solution to achieve the better tumor growth control against the radiation-induced toxicity of for the clinical application. Methods: Total of